Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.46
+0.34008.25%
Post-market: 4.460.00000.00%17:58 EDT
Volume:79.90K
Turnover:356.26K
Market Cap:248.61M
PE:-3.33
High:4.60
Open:4.24
Low:4.24
Close:4.12
Loading ...

Foghorn Therapeutics Inc. to Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
22 May

Promising Advancements and Strategic Collaborations Drive Buy Rating for Foghorn Therapeutics

TIPRANKS
·
15 May

Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Foghorn Therapeutics Reports Strong Cash Position with $220.6 Million, Ensures Cash Runway into 2027; No Specific Sales or EPS Data Disclosed

Reuters
·
14 May

BRIEF-Foghorn Therapeutics Q1 EPS USD -0.3

Reuters
·
14 May

Foghorn Therapeutics Q1 Net Income USD -18.834 Million

THOMSON REUTERS
·
14 May

Foghorn Therapeutics: Robust Balance Sheet, Cash Runway Into 2027; to Deliver High-Impact Therapeutics in 2025 and Beyond

THOMSON REUTERS
·
14 May

Foghorn Therapeutics Q1 EPS USD -0.3

THOMSON REUTERS
·
14 May

Press Release: Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Dow Jones
·
14 May

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
12 May

North American Morning Briefing: Stock Futures Down As Oil Plunges

Dow Jones
·
05 May

Foghorn Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Neil Gallagher

Reuters
·
03 May

Foghorn Therapeutics Inc. expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
02 May

Foghorn Therapeutics Inc. Appoints Neil Gallagher and Stuart Duty to Board of Directors to Strengthen Strategic Leadership

Reuters
·
01 May

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to Its Board of Directors

THOMSON REUTERS
·
01 May

Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Dow Jones
·
01 May

Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Apr

Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments

TIPRANKS
·
30 Apr

Analysts Are Bullish on Top Healthcare Stocks: Option Care Health (OPCH), Foghorn Therapeutics (FHTX)

TIPRANKS
·
30 Apr

Foghorn Therapeutics announces new preclinical data at AACR

TIPRANKS
·
29 Apr